In COVID-19 clinical update #50, Daniel Griffin discusses CDC guidance on school opening, decreased viral load after vaccination, randomized clinical trial of vitamin D treatment, a study of zinc plus vitamin C, anticoagulation therapy effect on mortality, and multi system inflammatory phase in children.
Paul Offit joins TWiV to discuss all things vaccine, including how COVID-19 vaccine development was accelerated, whether the vaccines are safe and efficacious, the difference between an EUA and a licensed vaccine, sterilizing immunity, herd immunity, and much more.
In COVID-19 clinical update #49, Daniel Griffin discusses CDC guidelines on mask use, drop in test frequency in the US, resurgence of COVID-19 in Brazil, possible impact of Pfizer vaccine on viral load, EUA for bamlanivimab and etesevimab administered together, and preliminary results of Tocilizumab in hospitalized patients.
TWiV explores single dose administration and timing of second dose of AZD1222 COVID-19 vaccine, safety and efficacy of Sputnik V, and control of coronavirus recombination by a viral proofreading exonuclease.
Theodora and Paul return to TWiV to explain how they quickly pivoted their retrovirus laboratories towards SARS-CoV-2, their work on the antibody response to infection and its durability, and the emergence of variants with increased resistance to neutralization.
In COVID-19 clinical update #48, Daniel Griffin reviews effect of spike amino acid changes on neutralization with monoclonal antibodies, Sputnik V safety and efficacy results, increased reactogenicity after a single vaccine dose in seropositive individuals, single dose vaccination in seropositive health care workers, and results of three clinical trials on the use of anticoagulants.
TWiV explains why hydroxychloroquine failed in humans despite showing antiviral effects in cells, and reviews the published data on the Pfizer/BioNTech mRNA vaccine.
Jason McLellan joins TWiV to reveal all we know about the SARS-CoV-2 spike protein, followed by Novavax and J&S phase 3 results and a discussion of variants of concern: neutralization by vaccine-induced antibodies, transmission, and virulence.
In COVID-19 clinical update #47, Daniel Griffin reviews phase 3 results for Novavax and J&J vaccines, transmission in K-12 settings in Wisconsin, data on Lilly and Regeneron monoclonal antibody therapy, and a study of colchicine for treatment of disease.
Gisa, Steffi, and César join TWiV to discuss their careers, their research, and the COVID-19 pandemic in Germany.